CRISPR: From Discovery To Clinic—And Charting A Path Forward
No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...
Oncology Nurse Advisor21h
CD70-Directed CAR-T Therapy Shows Promise in T-Cell Lymphoma
Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.
Q4 Earnings Surprise Greenlights CRISPR Therapeutics Stock Climb
CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...
Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
‘Much-needed hope’ as CRISPR gene editing therapy recommended for sickle cell disease
The therapy, which the UK’s medicines regulator cleared for ... adding that it provides “much-needed hope”. The discovery of ...
Medscape7d
Could Gene Therapy for RA Soon Be Ready to ‘Take Off’?
Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...
Personalized Cell Therapy Market: Growing at a CAGR of 25% From 2024-2032 | Pfizer, CARsgen Therapeutics, Mesoblast Ltd
Bristol Myers Squibb's FDA nod for Breyanzi (liso-cel) in relapsed/refractory CLL/SLL boosts its CAR T-cell portfolio, ...
CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...